Answers are grounded in this paper and cite their sources.
• GLP-1RA development traces a century of translational progress from gut hormones to multi-agonist therapeutics. • Rational protein engineering and delivery innovations transformed incretin biology into global metabolic therapeutics. • Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.
No takes yet. Share an insight, caveat, or question.
Darwish et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: